The monoclonal antibody denosumab prevents fractures and increases survival in breast cancer patients receiving aromatase inhibitors. Credit: Nancy R. Gough, BioSerendipity

New Options for Limiting the Side Effects of Anti-Estrogen Breast Cancer Therapy

Clinical trial results show that the monoclonal antibody denosumab is effective in preventing fractures associated with anti-estrogen therapy and extends disease-free survival of breast cancer patients.

Related Reading

Scientist, editor, and writer with a PhD in Pharmacology

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store